Evolus Raises FY24 Net Revenue Guidance From $255M - $265M To $260M - $270M, Est $262.495M
Portfolio Pulse from Benzinga Newsdesk
Evolus has raised its FY24 net revenue guidance to $260M - $270M, up from $255M - $265M, with an estimated $262.495M. The company expects an adjusted gross profit margin of 68%-71% for FY24 and aims for positive non-GAAP operating income in Q4 2024 and FY25. Evolus projects total net revenue to reach at least $700M by 2028, driven by its existing neurotoxin business and the anticipated launch of the Evolysse™ HA dermal filler product line in 2025.
July 31, 2024 | 9:31 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Evolus has increased its FY24 net revenue guidance and expects significant revenue growth through 2028, driven by its current and upcoming product lines.
The raised revenue guidance and positive future projections indicate strong business performance and growth potential, likely boosting investor confidence and positively impacting the stock price in the short term.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100